FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015469897> ?p ?o ?g. }

• W3015469897 abstract "This is an update to the review published in the Cochrane Library (2012, Issue 4).It is estimated that 20% to 40% of people with cancer will develop brain metastases during the course of their illness. The burden of brain metastases impacts quality and length of survival.To assess the effectiveness and adverse effects of whole brain radiotherapy (WBRT) given alone or in combination with other therapies to adults with newly diagnosed multiple brain metastases.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase to May 2017 and the National Cancer Institute Physicians Data Query for ongoing trials.We included phase III randomised controlled trials (RCTs) comparing WBRT versus other treatments for adults with newly diagnosed multiple brain metastases.Two review authors independently assessed trial quality and abstracted information in accordance with Cochrane methods.We added 10 RCTs to this updated review. The review now includes 54 published trials (45 fully published reports, four abstracts, and five subsets of data from previously published RCTs) involving 11,898 participants.Lower biological WBRT doses versus controlThe hazard ratio (HR) for overall survival (OS) with lower biological WBRT doses as compared with control (3000 cGy in 10 daily fractions) was 1.21 (95% confidence interval (CI) 1.04 to 1.40; P = 0.01; moderate-certainty evidence) in favour of control. The HR for neurological function improvement (NFI) was 1.74 (95% CI 1.06 to 2.84; P = 0.03; moderate-certainty evidence) in favour of control fractionation.Higher biological WBRT doses versus controlThe HR for OS with higher biological WBRT doses as compared with control (3000 cGy in 10 daily fractions) was 0.97 (95% CI 0.83 to 1.12; P = 0.65; moderate-certainty evidence). The HR for NFI was 1.14 (95% CI 0.92 to 1.42; P = 0.23; moderate-certainty evidence).WBRT and radiosensitisersThe addition of radiosensitisers to WBRT did not confer additional benefit for OS (HR 1.05, 95% CI 0.99 to 1.12; P = 0.12; moderate-certainty evidence) or for brain tumour response rates (odds ratio (OR) 0.84, 95% CI 0.63 to 1.11; P = 0.22; high-certainty evidence).Radiosurgery and WBRT versus WBRT aloneThe HR for OS with use of WBRT and radiosurgery boost as compared with WBRT alone for selected participants was 0.61 (95% CI 0.27 to 1.39; P = 0.24; moderate-certainty evidence). For overall brain control at one year, the HR was 0.39 (95% CI 0.25 to 0.60; P < 0.0001; high-certainty evidence) favouring the WBRT and radiosurgery boost group.Radiosurgery alone versus radiosurgery and WBRTThe HR for local brain control was 2.73 (95% CI 1.87 to 3.99; P < 0.00001; high-certainty evidence)favouring the addition of WBRT to radiosurgery. The HR for distant brain control was 2.34 (95% CI 1.73 to 3.18; P < 0.00001; high-certainty evidence) favouring WBRT and radiosurgery. The HR for OS was 1.00 (95% CI 0.80 to 1.25; P = 0.99; moderate-certainty evidence). Two trials reported worse neurocognitive outcomes and one trial reported worse quality of life outcomes when WBRT was added to radiosurgery.We could not pool data from trials related to chemotherapy, optimal supportive care (OSC), molecular targeted agents, neurocognitive protective agents, and hippocampal sparing WBRT. However, one trial reported no differences in quality-adjusted life-years for selected participants with brain metastases from non-small-cell lung cancer randomised to OSC and WBRT versus OSC alone.None of the trials with altered higher biological WBRT dose-fractionation schemes reported benefit for OS, NFI, or symptom control compared with standard care. However, OS and NFI were worse for lower biological WBRT dose-fractionation schemes than for standard dose schedules.The addition of WBRT to radiosurgery improved local and distant brain control in selected people with brain metastases, but data show worse neurocognitive outcomes and no differences in OS.Selected people with multiple brain metastases from non-small-cell lung cancer may show no difference in OS when OSC is given and WBRT is omitted.Use of radiosensitisers, chemotherapy, or molecular targeted agents in conjunction with WBRT remains experimental.Further trials are needed to evaluate the use of neurocognitive protective agents and hippocampal sparing with WBRT. As well, future trials should examine homogeneous participants with brain metastases with focus on prognostic features and molecular markers." @default.
• W3015469897 created "2020-04-17" @default.
• W3015469897 creator A5001373416 @default.
• W3015469897 creator A5015138770 @default.
• W3015469897 creator A5031847465 @default.
• W3015469897 creator A5036667918 @default.
• W3015469897 creator A5044565573 @default.
• W3015469897 creator A5047114036 @default.
• W3015469897 creator A5069616282 @default.
• W3015469897 creator A5082764228 @default.
• W3015469897 date "2018-01-25" @default.
• W3015469897 modified "2023-10-14" @default.
• W3015469897 title "Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases" @default.
• W3015469897 cites W1265487864 @default.
• W3015469897 cites W1480729244 @default.
• W3015469897 cites W1566600962 @default.
• W3015469897 cites W1577231758 @default.
• W3015469897 cites W1895100970 @default.
• W3015469897 cites W1902158572 @default.
• W3015469897 cites W1911884635 @default.
• W3015469897 cites W1922266404 @default.
• W3015469897 cites W1964905218 @default.
• W3015469897 cites W1972132550 @default.
• W3015469897 cites W1973332545 @default.
• W3015469897 cites W1974820090 @default.
• W3015469897 cites W1977581065 @default.
• W3015469897 cites W1986215651 @default.
• W3015469897 cites W1994362655 @default.
• W3015469897 cites W1994898034 @default.
• W3015469897 cites W1995597507 @default.
• W3015469897 cites W2000085543 @default.
• W3015469897 cites W2001729667 @default.
• W3015469897 cites W2002859650 @default.
• W3015469897 cites W2004451956 @default.
• W3015469897 cites W2004630726 @default.
• W3015469897 cites W2025578395 @default.
• W3015469897 cites W2025727766 @default.
• W3015469897 cites W2028835275 @default.
• W3015469897 cites W2031659676 @default.
• W3015469897 cites W2034544297 @default.
• W3015469897 cites W2035712312 @default.
• W3015469897 cites W2037550193 @default.
• W3015469897 cites W2038693293 @default.
• W3015469897 cites W2040059131 @default.
• W3015469897 cites W2041208884 @default.
• W3015469897 cites W2047930883 @default.
• W3015469897 cites W2051841816 @default.
• W3015469897 cites W2057324286 @default.
• W3015469897 cites W2057691996 @default.
• W3015469897 cites W2058316012 @default.
• W3015469897 cites W2061962226 @default.
• W3015469897 cites W2064427333 @default.
• W3015469897 cites W2069787488 @default.
• W3015469897 cites W2071990624 @default.
• W3015469897 cites W2075642745 @default.
• W3015469897 cites W2078763461 @default.
• W3015469897 cites W2095813725 @default.
• W3015469897 cites W2102113843 @default.
• W3015469897 cites W2102149158 @default.
• W3015469897 cites W2107529266 @default.
• W3015469897 cites W2109523793 @default.
• W3015469897 cites W2111406583 @default.
• W3015469897 cites W2113465576 @default.
• W3015469897 cites W2113517821 @default.
• W3015469897 cites W2128871519 @default.
• W3015469897 cites W2131359324 @default.
• W3015469897 cites W2135121296 @default.
• W3015469897 cites W2137510882 @default.
• W3015469897 cites W2143843774 @default.
• W3015469897 cites W2148411131 @default.
• W3015469897 cites W2153127029 @default.
• W3015469897 cites W2154563173 @default.
• W3015469897 cites W2154704485 @default.
• W3015469897 cites W2158789700 @default.
• W3015469897 cites W2165694430 @default.
• W3015469897 cites W2170550919 @default.
• W3015469897 cites W2170736271 @default.
• W3015469897 cites W2170736348 @default.
• W3015469897 cites W2177244913 @default.
• W3015469897 cites W2321905436 @default.
• W3015469897 cites W2327274121 @default.
• W3015469897 cites W2334614836 @default.
• W3015469897 cites W2409020857 @default.
• W3015469897 cites W2429254977 @default.
• W3015469897 cites W2492450141 @default.
• W3015469897 cites W2510132475 @default.
• W3015469897 cites W2558464985 @default.
• W3015469897 cites W2766357896 @default.
• W3015469897 cites W3021723106 @default.
• W3015469897 cites W3140068819 @default.
• W3015469897 cites W4239413529 @default.
• W3015469897 doi "https://doi.org/10.1002/14651858.cd003869.pub4" @default.
• W3015469897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29365347" @default.
• W3015469897 hasPublicationYear "2018" @default.
• W3015469897 type Work @default.
• W3015469897 sameAs 3015469897 @default.
• W3015469897 citedByCount "86" @default.
• W3015469897 countsByYear W30154698972018 @default.
• W3015469897 countsByYear W30154698972019 @default.
• W3015469897 countsByYear W30154698972020 @default.

• next